Advertisement

The European Journal of Health Economics

, Volume 19, Issue 3, pp 471–472 | Cite as

Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

  • Afschin Gandjour
Commentary
The paper by Kuhlmann and Graf von der Schulenburg [ 1] suffers from a number of shortcomings. First, the QALY calculation is flawed. Based on the data provided in Table  9of their article (see below), dividing the number of QALYs gained by the number of life years gained yields a ratio of just 0.56. Yet, this ratio cannot be explained by the QALY weights listed in Table 6 (as a side note, the base-case values listed in Table 6 for the complications of pneumococcal infection need to refer to a loss of health-related quality of life and not to health-related quality of life per se, as presented). Even if PCV13 were purely life extending, the ratio would be larger as the lowest QALY weight in the population without pneumococcal infection is already 0.59. But in addition to its life extending effect the vaccine, of course, prevents pneumococcal infection and its complications which further increases the number of QALYs gained and therefore increases the ratio of number of QALYs to number...

References

  1. 1.
    Kuhlmann, A., von der Schulenburg, J.G.: Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ 18(3), 273–292 (2017)CrossRefPubMedGoogle Scholar
  2. 2.
    Garrison Jr., L.P., Mansley, E.C., Abbott 3rd, T.A., Bresnahan, B.W., Hay, J.W., Smeeding, J.: Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective. The ISPOR Drug Cost Task Force report–Part II. Value Health 13(1), 8–13 (2010)CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Frankfurt School of Finance and ManagementFrankfurt am MainGermany

Personalised recommendations